TBPMF Stock - Tetra Bio-Pharma Inc.
Unlock GoAI Insights for TBPMF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $112,320 | N/A |
| Gross Profit | N/A | N/A | N/A | $44,729 | N/A |
| Gross Margin | N/A | N/A | N/A | 39.8% | N/A |
| Operating Income | $-24,841,290 | $-19,941,094 | $-13,386,171 | $-15,202,910 | $-6,097,726 |
| Net Income | $-52,175,046 | $-26,476,177 | $-15,282,933 | $-7,572,555 | $-6,225,294 |
| Net Margin | N/A | N/A | N/A | -6741.9% | N/A |
| EPS | $-0.12 | $-0.10 | $-0.08 | $-0.05 | $-0.06 |
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.
Visit WebsiteEarnings History & Surprises
TBPMFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2023 | Oct 16, 2023 | — | — | — | — |
Q3 2023 | Aug 25, 2023 | — | — | — | — |
Q2 2023 | May 19, 2023 | — | — | — | — |
Q1 2023 | Feb 27, 2023 | — | — | — | — |
Q4 2022 | Oct 16, 2022 | — | $-0.01 | — | — |
Q3 2022 | Jul 14, 2022 | — | $-0.01 | — | — |
Q2 2022 | Apr 13, 2022 | — | $-0.00 | — | — |
Q1 2022 | Feb 28, 2022 | — | $-0.02 | — | — |
Q4 2021 | Oct 13, 2021 | — | $-0.01 | — | — |
Q3 2021 | Jul 14, 2021 | — | $-0.02 | — | — |
Q2 2021 | Apr 13, 2021 | — | $-0.02 | — | — |
Q1 2021 | Feb 17, 2021 | — | $-0.02 | — | — |
Q4 2020 | Nov 30, 2020 | — | $-0.02 | — | — |
Q3 2020 | Jul 20, 2020 | — | $-0.01 | — | — |
Q2 2020 | Apr 28, 2020 | — | $-0.01 | — | — |
Q1 2020 | Mar 25, 2020 | — | $-0.02 | — | — |
Q4 2019 | Oct 18, 2019 | — | $-0.01 | — | — |
Q3 2019 | Jul 25, 2019 | — | $-0.01 | — | — |
Q2 2019 | Apr 26, 2019 | — | $-0.02 | — | — |
Q1 2019 | Mar 15, 2019 | — | $-0.01 | — | — |
Latest News
Frequently Asked Questions about TBPMF
What is TBPMF's current stock price?
What is the analyst price target for TBPMF?
What sector is Tetra Bio-Pharma Inc. in?
What is TBPMF's market cap?
Does TBPMF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TBPMF for comparison